The short version of 反相色谱 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-29 and is reviewed periodically as new material appears.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Trial design | Randomized, double-blind, placebo-controlled | Frequently includes dose-escalation arms |
| Weight endpoint | Percent change from baseline | Reported at a prespecified week |
| Liver fat endpoint | MRI proton density fat fraction | Non-invasive imaging measure |
| Body composition method | Dual-energy X-ray absorptiometry | Separates fat mass from lean mass |
| Common adverse events | Nausea, diarrhea, vomiting | Reported most often during dose escalation |
Peptide content and purity are commonly measured by reversed-phase high-performance liquid chromatography with ultraviolet detection, using gradient elution over a C18 column. Identity is confirmed by mass spectrometry, because the theoretical monoisotopic mass allows unambiguous assignment of the main component. Impurity profiling resolves deletion sequences, oxidized residues, and truncated fragments. Since the molecule carries a lipophilic side chain, mobile phases often include ion-pairing agents and organic modifiers to keep peaks symmetric.
Lyophilized material is generally held at minus 20 degrees Celsius or colder for long-term storage, protected from moisture and light. Solutions are handled under refrigeration, typically between 2 and 8 degrees Celsius, and used within a short window because degradation and microbial growth both accelerate in liquid. Repeated freeze-thaw cycles are avoided, and vials are equilibrated to room temperature before opening to reduce condensation. These are general laboratory conventions for peptides of this size rather than product-specific directions.
Characterization panels may add amino acid analysis for compositional confirmation, circular dichroism for secondary structure in solution, and light scattering for aggregation tendency. Aggregation is a central concern for peptides bearing hydrophobic side chains, since it can lower measured potency and complicate accurate dosing. Stability studies examine temperature, humidity, pH, and light exposure over defined intervals, reporting the percentage of intact peptide remaining. Results depend strongly on the assay used, so comparing values across studies requires matching method details.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
该分子是经过结构修饰的合成肽，通过脂肪酸侧链与白蛋白结合，从而延长循环时间。皮下给药后，药物逐步释放并分布至组织。降解主要依赖蛋白酶，肾脏清除占次要地位。人体半衰期以天为单位，但准确数值随检测方法和个体差异而变；组织分布与受体占有率仍是开放问题。
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
== Conservation == In 1997, kutki was listed in appendix II of the Convention on International Trade in Endangered Species (CITES). This listing resulted ultimately from a request by the Indian government. Overharvesting of the wild species for use as medicine was cited as the main reason for the listing. The species is not widely cultivated, though this has been discussed as a potential way to preserve wild stands, especially since the Dunagiri Foundation Trust has created, implemented, and successfully employed protocols to generate export-quality organic ethical 'Dunagiri Certified' Kutki since 2014. The International Union for Conservation of Nature Red List did not have a listing for this species as of 2014. Picrorhiza scrophulariiflora appears to be used heavily as a substitute for P. kurroa and is considered non-threatened by CITES.
=== Dulling of a chain === Chains will naturally dull over time with use. The friction cause by cutting wood gradually wears the chain's teeth down. However, the technique of use can also contribute to a chain dulling quickly. Cutting at too sharp an angle, cutting into dirt, and cutting frozen wood can prematurely dull your chain.
Geckos, skinks, and some other lizards that are captured by the tail will shed part of the tail structure through a process called autotomy and thus be able to flee. The detached tail will continue to thrash, creating a deceptive sense of continued struggle and distracting the predator's attention from the fleeing prey animal. The detached tails of leopard geckos can wiggle for up to 20 minutes. The tail grows back in most species, but some, like crested geckos, lose their tails for the rest of their lives. In many species the tails are of a separate and dramatically more intense color than the rest of the body so as to encourage potential predators to strike for the tail first. In the shingleback skink and some species of geckos, the tail is short and broad and resembles the head, so that the predators may attack it rather than the more vulnerable front part. Reptiles that are capable of shedding their tails can partially regenerate them over a period of weeks. The new section will however contain cartilage rather than bone, and will never grow to the same length as the original tail. It is often also distinctly discolored compared to the rest of the body and may lack some of the external sculpting features seen in the original tail.
== Further reading == Sugo T, Mori M (May 2008). "Another ligand fishing for G protein-coupled receptor 14. Discovery of urotensin II-related peptide in the rat brain". Peptides. 29 (5): 809–812. doi:10.1016/j.peptides.2007.06.005. PMID 17628210. S2CID 13387250. Nothacker HP, Clark S (November 2005). "From heart to mind. The urotensin II system and its evolving neurophysiological role". The FEBS Journal. 272 (22): 5694–5702. doi:10.1111/j.1742-4658.2005.04983.x. PMID 16279935.
Sources: en.wikipedia.org
== External links == Understanding Pompe Disease - US National Institute of Arthritis and Musculoskeletal and Skin Diseases AGSD — Association of Glycogen Storage Disease in the United States AGSD-UK — Association of Glycogen Storage Disease in the UK AMDA — Acid Maltase Deficiency Association (Pompe disease) IPA — International Pompe Association IamGSD — International Association for Muscle Glycogen Storage Disease
A diplomatic crisis began in 2025 when the Donald Trump's second presidency of the United States administration sought to annex Greenland, an autonomous territory of the Danish Realm—a treaty ally of the United States and co-member of NATO, and a member of the European Union (EU). The crisis intensified in early 2026 when Trump refused to rule out the use of military force for this annexation and threatened a 25% import tax on goods from several European nations unless Denmark ceded the territory to the United States. Denmark's refusal was supported by the EU and several other NATO members, reigniting earlier concerns of a US–EU trade war. Within weeks, Trump backed down, pledging not to use force or tariffs to annex Greenland. Trump had tried to purchase Greenland during his first presidency. After his 2024 re-election, in January 2026, he said "it may be a choice" whether to preserve NATO or seize Greenland, and in Dear Jonas, a letter leaked by Norwegian Prime Minister Jonas Gahr Støre, Trump had said that he "no longer [felt] an obligation to think purely of Peace" after not receiving the Nobel Peace Prize. A report by the Danish Defence Intelligence Service mentioned the United States as a potential threat to national security for the first time in its history, and Danish officials raised concerns about reports that Director of National Intelligence Tulsi Gabbard had assigned agents to spy on Greenland. The Greenlandic and Danish prime ministers rejected any American takeover, saying they would defend Greenland in the event of an attack.
Macrophages are professional phagocytes and are highly specialized in removal of dying or dead cells and cellular debris. This role is important in chronic inflammation, as the early stages of inflammation are dominated by neutrophils, which expend themselves and are ingested by macrophages. Macrophages normally present themselves at the wound site within 2 days following the injury. The neutrophils are at first attracted to a site, where they perform their function and die, before they or their neutrophil extracellular traps are phagocytized by the macrophages. The first wave of neutrophils acts for approximately 2 days at the site and signals to attract macrophages. These macrophages will then ingest the aged neutrophils. The removal of dying cells is, to a greater extent, handled by fixed macrophages, which will stay at strategic locations such as the lungs, liver, neural tissue, bone, spleen and connective tissue, ingesting foreign materials such as pathogens and recruiting additional macrophages if needed. The phagocytosis and clearance of apoptotic remains is called efferocytosis and is also carried out by other cell types, not all of which are professional phagocytes. When a macrophage ingests a pathogen, the pathogen becomes trapped in a phagosome, which then fuses with a lysosome. Within the phagolysosome, enzymes and toxic peroxides digest the pathogen. However, some bacteria (such as Mycobacterium tuberculosis) have become resistant to these methods of digestion.
Sources: en.wikipedia.org
Nickel(II) forms compounds with all common anions, including sulfide, sulfate, carbonate, hydroxide, carboxylates, and halides. Nickel(II) sulfate is produced in large amounts by dissolving nickel metal or oxides in sulfuric acid, forming both a hexa- and heptahydrate useful for electroplating nickel. Common salts of nickel, such as chloride, nitrate, and sulfate, dissolve in water to give green solutions of the metal aquo complex [Ni(H2O)6]2+. The four halides form nickel compounds, which are solids with molecules with octahedral Ni centres. Nickel(II) chloride is most common, and its behavior is illustrative of the other halides. Nickel(II) chloride is made by dissolving nickel or its oxide in hydrochloric acid. It is usually found as the green hexahydrate, whose formula is usually written NiCl2·6H2O. When dissolved in water, this salt forms the metal aquo complex [Ni(H2O)6]2+. Dehydration of NiCl2·6H2O gives yellow anhydrous NiCl2. Some tetracoordinate nickel(II) complexes, e.g. bis(triphenylphosphine)nickel chloride, exist both in tetrahedral and square planar geometries. The tetrahedral complexes are paramagnetic; the square planar complexes are diamagnetic. In having properties of magnetic equilibrium and formation of octahedral complexes, they contrast with the divalent complexes of the heavier group 10 metals, palladium(II) and platinum(II), which form only square-planar geometry. Nickelocene has an electron count of 20. Many chemical reactions of nickelocene tend to yield 18-electron products.
=== Iceland in 1986 === In 1986, at the age of 20, whilst at the University of Leeds, he crossed Iceland, together with three other students (Andrew Backhouse, David Brock and Shaun Fagan), from Seyðisfjörður in the east, through the interior to the north of the Vatnajökull ice fields, and then west to Reykjavík. The team encountered an 'ash storm', where storm force winds had whipped up fine black volcanic ash, and had to wear goggles and face masks to push on into the winds. In the rain shadow of the Vatnajökull, they ran out of water, then encountered a flash flood, as mud rushed down from the melting glaciers. They also had to survive on food contaminated with petrol that had leaked from their petrol stoves. This journey of 400 miles (640 km) raised £2,000 for the Royal Association for Disability and Rehabilitation. As part of the training for the walk across Iceland he ran the Leeds Marathon, in a time of 3 hours and 41 minutes. On the Icelandic trek, he came up with the idea of walking 6,000 miles (9,700 km), across Britain and America to raise money for Macmillan Cancer Support in Britain and hospice in America and Canada.
Some HCAs found in cooked and especially burned meat are known carcinogens. Research has shown that heterocyclic amine formation in meat occurs at high cooking temperatures. Heterocyclic amines are the carcinogenic chemicals formed from cooking muscle meats such as beef, lamb, pork, fish and poultry. HCAs form when amino acids and creatine (a chemical found in muscles) react at high cooking temperatures. Colorectal cancer is associated with high intakes of HCAs found in meat cooked at high temperature. Six hours of marinating in beer or red wine cut levels of two types of HCA in beef steak by up to 90% compared with unmarinated steak.
Sources: en.wikipedia.org
A responder analysis counts participants who cross a threshold, such as five or ten percent weight loss. It complements average percent change by showing how widely results are distributed. The two measures can diverge when a subset of participants loses a large amount.
Mechanistic measures such as energy expenditure and liver fat change come from small substudies and should be read as preliminary. Long-term clinical outcomes are not yet available. Average weight loss figures are better supported than explanations for how the loss is achieved.
Endpoints reported at different weeks, in different baseline BMI ranges, or under different dose-escalation schedules are not directly comparable. Studies in type 2 diabetes often show smaller weight changes than studies in obesity without diabetes. Reporting the population alongside the number keeps comparisons honest.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.